https://doi.org/10.55788/127f37bb
Weight loss intervention to decrease breathlessness has previously shown promise in improving quality of life, reducing dyspnoea, and the number of exacerbations in patients with chronic lung disease [1]. This was the rationale for a small-scale study, presented by Dr Maria Benzo (Mayo Clinic Rochester, MN, USA) [2].
The study recruited 25 patients with a diagnosis of chronic lung disease who had a BMI >35 and dyspnoea of Medical Research Council class II or greater. Participants received 12 weeks of health coaching, Weight Watchers online programme with a daily food log, a fitness tracer wearable wristband, and a Bluetooth scale for weigh-ins at home.
The primary outcome measures were weight, quality of life, and dyspnoea improvement. Measurements were taken at baseline and at 3 and 6 months of follow-up. Of the 25 participants, only 13 finished the intervention, and data of only 10 was available at the 6-month follow-up. From baseline to 3 months, the average weight loss was 18.4 lbs (8.3 kg) or 6.9% of the total body weight (95% CI -25.2 to -11.7; P=0.00007). Likewise, dyspnoea was also reduced by 0.6 points (95% CI 0.2ā1.1; P=0.00919). No other variables measured were significantly different, including quality of life, number of steps, or fatigue. At the 6-month follow-up, the average weight loss was 22.4 lbs (10.2 kg) or 9% of baseline body weight.
Dr Benzo concluded that acquiring healthy behaviours and self-awareness through registering food intake, checking daily steps, and weekly health coaching calls resulted in improved dyspnoea and weight loss.
- Dupuy-McCauley KL, et al. Chest. 2020;158(3):1128ā1131.
- Benzo M, et al. Lifestyle Intervention Targeting Weight Loss to Reduce Dyspnea in Chronic Lung Disease. Session A93, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« CT-evident mucus plugs in COPD associated with death Next Article
Higher 1-year COPD mortality after hospitalisation for White patients »
« CT-evident mucus plugs in COPD associated with death Next Article
Higher 1-year COPD mortality after hospitalisation for White patients »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 30, 2022
Sustained hypoxaemia predicts unprovoked VTE in OSA
October 29, 2020
CPAP withdrawal has negative consequences for sleep apnoea patients
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com